



Anti-inflammatory and cytotoxic specialised metabolites from the leaves of *Glandularia × hybrida*

Nesma M. Mohamed^a, Mai A.M. Ahmed^a, Shabana I. Khan^{b,c}, Frank R. Fronczek^d,
Anber F. Mohammed^e, Samir A. Ross^{b,c,*}

^a Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut, 71526, Egypt

^b National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS, 38677, USA

^c Division of Pharmacognosy, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS, 38677, USA

^d Department of Chemistry, Louisiana State University, Baton Rouge, LA, 70803, USA

^e Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University, Assiut, 71526, Egypt

ARTICLE INFO

Keywords:

Glandularia × hybrida
Verbenaceae
Triterpenoidal saponins
Lignans
X-ray crystallography
iNOS inhibition
Molecular docking

ABSTRACT

In our ongoing effort to investigate active specialised metabolites from genus *Glandularia*, phytochemical studies on the ethanolic extract of *Glandularia × hybrida* (Groenl. & Rümpler) G.L. Nesom & Pruski leaves resulted in the isolation of three undescribed compounds, a dibenzylbutyrolactolic lignan and two echinocystic acid based triterpenoid saponins, in addition to two known compounds. Interestingly, this study reports isolation of chemo-systematically valuable specialised metabolites for the first time from the genus under investigation. Additionally, the isolated metabolites were evaluated for their iNOS inhibition and cytotoxic activities using a combination of *in silico* and *in vitro* studies. The pharmacokinetics properties (ADMET) of some of the isolated compounds were determined using pkCSM-pharmacokinetics server. Molecular docking analysis showed that saponin compound possesses higher negative score (−9.59 kcal/mol) than the lignan compound (−6.56 kcal/mol). The isolated compounds also showed iNOS inhibition activity with IC₅₀ values ranging between 6.6 and 49.7 μM and significant cytotoxic activity against a series of cell lines including SK-MEL, KB, BT-549, SK-OV-3, LLC-PK1 and VERO cells. Hence, this study reveals that specialised metabolites from *G. hybrida* plant are of significant anti-inflammatory and cytotoxicity potentials.

1. Introduction

Glandularia J. F. Gmel. (Verbenaceae) is a genus of about 84 species, mainly distributed in the temperate areas of North and South America (O'Leary and Thode, 2016). It is one of the genera which is phylogenetically linked to the genus *Verbena*. It is considered as a sister genus in the *Verbena* complex that comprises three genera i.e. *Verbena*, *Glandularia* and *Junellia* (Yuan and Olmstead, 2008). Recent phytochemical studies on the genus *Glandularia* have reported the identification of saponins, iridoids and flavonoids (Vestena et al., 2019; Mohamed et al., 2020; Ahmed et al., 2021). Unlike *Verbena*, no extensive investigation has been conducted on the phytoconstituents of *Glandularia*. *Glandularia × hybrida* (Groenl. & Rümpler) G. L. Nesom & Pruski was known as *Verbena × hybrida* (Pruski and Nesom, 1992). It is an annual,

floricultural, very charming ornamental plant, and commonly named as Garden Verbena (Mabberley, 2017). Our previous phytochemical and biological studies on *G. hybrida* roots revealed the presence of ursane and oleanane-type triterpenoid saponins with notable anti-inflammatory activity (Mohamed et al., 2020). Thus, we become more interested in these scaffolds and this provoked us to profile the characteristic specialised metabolites of the leaves of *G. hybrida*. Interestingly, this study reports chemo-systematically significant isolation and identification of three undescribed compounds (1–3) i.e. a dibenzylbutyrolactolic lignan and two echinocystic acid based triterpenoid saponins, from the ethanolic extract of *G. hybrida* leaves for the first time from this genus. The compounds were evaluated for their *in vitro* cytotoxic activity against human cancer cell lines including SK-MEL, KB, BT-549, SK-OV-3 and LLC-PK1 cells. The anti-inflammatory activity of

* Corresponding author. National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS, 38677, USA.

E-mail address: sross@olemiss.edu (S.A. Ross).

<https://doi.org/10.1016/j.phytochem.2021.113054>

Received 29 August 2021; Received in revised form 6 December 2021; Accepted 8 December 2021

Available online 31 December 2021

0031-9422/© 2021 Elsevier Ltd. All rights reserved.

the isolated compounds was also determined through cellular assay targeting the inhibition potential of the compounds against iNOS inflammatory mediator. Inhibitory activity of isolated compounds against iNOS was evaluated using both *in silico* and *in vitro* studies.

2. Results and discussion

The defatted fraction obtained from the ethanolic extract of *G. hybrida* leaves was subjected to a series of chromatographic techniques to afford five compounds (1-5), from which three compounds (1-3) are previously undescribed. They were identified as dibenzylbutyrolactolic lignan (1) and echinocystic acid based triterpenoidal saponins (2 and 3), with their structures elucidated on the basis of 1D, 2D-NMR and HRESIMS. The ^1H and ^{13}C -NMR data are shown in Tables 1 and 2, and the spectra are given in the Supporting Information (Figures S1–S24).

2.1. Structural elucidation of isolated compounds

Compound 1 was obtained as a colourless residue, its molecular formula was deduced as $\text{C}_{20}\text{H}_{20}\text{O}_7$ on the basis of molecular ion peaks $[\text{M}-\text{H}]^-$ at m/z 371.1176 (calcd. for $\text{C}_{20}\text{H}_{19}\text{O}_7$, 371.1131), and $[\text{M} + \text{HCOO}]^-$ at m/z 417.1219 (calcd. for $\text{C}_{21}\text{H}_{21}\text{O}_9$, 417.1191) in negative mode HRESIMS (Fig. S8). The ^1H -NMR spectrum (Fig. S1) (Table 1) showed two singlets at δ_{H} 5.94 and 5.95 (s, C-10 & 10') characteristic for two aromatic methylenedioxy groups. A group of signals, six protons appeared between δ_{H} 6.55 and 6.80, attributable to six aromatic protons characteristic for two moieties of 1,3,4-tri-substituted aromatic rings. In addition, ^1H -NMR spectrum (Table 1) displayed signals for a methine group at δ_{H} 2.39 (m, H-8'), an oxygenated methine at δ_{H} 4.72 (d, $J = 4.0$ Hz, H-9), an oxygenated methylene at δ_{H} 3.53 (t, $J = 6.4$ Hz, H-9a') and δ_{H} 3.70 (t, $J = 6.4$ Hz, H-9b'), two benzylic protons at δ_{H} 2.69 (d, $J = 10.8$ Hz, H-7a) and δ_{H} 2.79 (d, $J = 10.8$ Hz, H-7b), as well as another two benzylic protons appear at δ_{H} 2.37 (m, H-7'). The ^{13}C -NMR spectrum (Fig. S2 and S3) (Table 1), in combination with the HMQC spectrum (Fig. S4), showed signals for twenty carbon atoms, twelve aromatic carbons including six quaternary carbons and six tertiary carbons (δ_{C} 107.5–147.2), an oxygenated methylene carbon (δ_{C} 71.1), two di-oxygenated methylene carbons (δ_{C} 100.4 & 100.6), a di-oxygenated methine carbon (δ_{C} 102.8), an oxygenated quaternary carbon (δ_{C}

Table 1
 ^1H and ^{13}C -NMR data of compound 1 (400/100 MHz, δ in ppm, J values in Hz) in DMSO- d_6

| Position | δ_{C} | δ_{H} |
|----------|---------------------|----------------------------------|
| 1 | 132.0 | – |
| 2 | 110.9 | 6.91 (br s) |
| 3 | 147.2 | – |
| 4 | 145.2 ^b | – |
| 5 | 107.5 | 6.78 ^a |
| 6 | 123.5 | 6.80 ^a |
| 7 | 39.9 | 2.69 (d, 10.8) 2.79 (d, 10.8) |
| 8 | 81.1 | – |
| 9 | 102.8 | 4.72 (d, 4.0) |
| 1' | 134.9 | – |
| 2' | 108.8 | 6.73 (d, 1.6) |
| 3' | 146.5 | – |
| 4' | 145.3 ^b | – |
| 5' | 108.1 | 6.79 ^a |
| 6' | 121.1 | 6.60 (dd, 8.0, 1.6) |
| 7' | 31.9 | 2.37 (m) |
| 8' | 45.9 | 2.39 (m) |
| 9' | 71.1 | 3.53 (t, 6.4) 3.70 (t, 6.4) |
| 10 | 100.4 ^b | 5.94 (s) |
| 10' | 100.6 ^b | 5.95 (s) |

^a Unclear signal pattern due to overlapping.

^b Values are interchangeable.

Table 2
 ^1H and ^{13}C -NMR data of compounds 2 and 3 (δ in ppm, J values in Hz)

| Position | Compounds | | | |
|------------------------------------|----------------------|---------------------|--|---------------------|
| | 2 ^b | | 3 ^c | |
| | δ_{H} | δ_{C} | δ_{H} | δ_{C} |
| 1 | 1.50 (m) 0.95 (m) | 39.4 | 1.49 (m) 0.88 (m) | 38.3 |
| 2 | 2.26 (m) 1.89 (m) | 27.2 | 1.83 (m) 1.50 (m) | 25.7 |
| 3 | 3.41 (dd, 9.6, 3.2) | 89.4 | 3.01 ^a | 88.7 |
| 4 | – | 40.0 | – | 38.7 |
| 5 | 0.82 (m) | 56.4 | 0.65 (m) | 55.6 |
| 6 | 1.50 (m) 1.37 (m) | 19.1 | 1.44 (m) 1.22 (m) | 17.7 |
| 7 | 1.65 (m) 1.46 (m) | 34.0 | 1.36 (m) 1.26 (m) | 32.6 |
| 8 | – | 40.5 | – | 39.8 |
| 9 | 1.78 (m) | 47.6 | 1.50 (t, 9.6) | 46.5 |
| 10 | – | 37.5 | – | 36.4 |
| 11 | 1.96 (m) | 24.4 | 1.79 (m) | 22.8 |
| 12 | 5.65 (br s) | 123.5 | 5.22 (br s) | 122.0 |
| 13 | – | 144.9 | – | 143.8 |
| 14 | – | 42.6 | – | 41.2 |
| 15 | 2.23 (m) 1.85 (m) | 36.6 | 1.58 ^a 1.23 ^a | 34.7 |
| 16 | 5.31 (br s) | 74.5 | 4.38 (br s) | 72.5 |
| 17 | – | 50.1 | – | 48.3 |
| 18 | 3.61 (br d, 13.8) | 41.8 | 2.90 ^a | 40.1 |
| 19 | 1.39 (m) 2.81 (m) | 47.7 | 0.95 (m) 2.20 (t, 12.4) | 46.3 |
| 20 | – | 31.5 | – | 30.2 |
| 21 | 2.44 (m) 1.32 (m) | 36.5 | 1.88 (m) 1.04 (m) | 35.0 |
| 22 | 2.35 (m) 2.22 (m) | 32.7 | 1.77 (m) 1.59 (m) | 31.1 |
| 23 | 1.31 (s) | 28.8 | 0.93 (s) | 27.8 |
| 24 | 1.01 (s) | 17.6 | 0.71 (s) | 16.6 |
| 25 | 0.88 (s) | 16.3 | 0.83 (s) | 15.7 |
| 26 | 1.12 (s) | 18.1 | 0.61 (s) | 17.1 |
| 27 | 1.83 (s) | 27.8 | 1.27 (s) | 26.8 |
| 28 | – | 176.5 | – | 175.2 |
| 29 | 1.04 (s) | 33.8 | 0.81 (s) | 33.2 |
| 30 | 1.18 (s) | 25.3 | 0.88 (s) | 24.6 |
| 3-O- β -D-Glu | | | | |
| 1 | 4.95 (d, 8.0) | 107.4 | 4.23 (d, 7.6) | 104.4 |
| 2 | 4.07 (m) | 76.3 | 3.14 (m) | 78.2 |
| 3 | 4.27 (m) | 79.2 | 3.25 (m) | 77.4 |
| 4 | 4.15 (m) | 71.7 | 3.03 (m) | 70.9 |
| 5 | 4.02 (m) | 78.7 | 3.78 ^a | 77.1 |
| 6 | 4.43 (m) 4.58 (m) | 62.8 | 3.70 ^a 3.39 ^a | 61.1 |
| β -D-Apiose (at C-2 Glu) | | | | |
| 1 | – | – | 5.28 (d, 2.4) | 109.4 |
| 2 | – | – | 3.80 (d, 2.4) | 76.8 |
| 3 | – | – | – | 79.3 |
| 4 | – | – | 3.86 (d, 7.6) 3.52 ^a | 73.9 |
| 5 | – | – | 3.33 (m) | 64.1 |
| 28-O- α -L-Ara (ester) | | | | |
| 1 | 6.56 (br s) | 93.7 | 5.52 (br s) | 91.9 |
| 2 | 4.55 (m) | 76.3 | 3.56 (m) | 76.3 |
| 3 | 4.61 (m) | 69.9 | 3.64 ^a | 70.2 |
| 4 | 4.47 (m) | 66.1 | 3.63 ^a | 64.3 |
| 5 | 3.97 (m) 4.58 (m) | 63.5 | 3.61 (m) 3.39 (m) | 61.4 |
| α -L-Rham-I (at C-2 Ara) | | | | |
| 1 | 5.66 (br s) | 101.9 | 4.76 (br s) | 99.3 |
| 2 | 4.72 (m) | 72.3 | 3.67 ^a | 70.5 |
| 3 | 4.56 (m) | 81.6 | 3.65 ^a | 79.1 |
| 4 | 4.54 (m) | 77.9 | 3.52 (m) | 76.8 |
| 5 | 4.39 (m) | 69.5 | 3.48 ^a | 67.7 |
| 6 | 1.73 (d, 6.4) | 19.2 | 1.09 (d, 6.0) | 18.1 |
| α -L-Rham-II (at C-3 Rha-I) | | | | |
| 1 | 5.85 (br s) | 105.0 | 4.81 (br s) | 102.7 |
| 2 | 5.07 (br s) | 72.8 | 3.77 ^a | 70.5 |
| 3 | 4.59 (m) | 73.3 | 3.50 (m) | 70.2 |

(continued on next page)

Table 2 (continued)

| Position | Compounds | | | |
|--|-------------------|------------|-------------------|------------|
| | 2 ^b | | 3 ^c | |
| | δ_H | δ_C | δ_H | δ_C |
| 4 | 4.28 (m) | 74.6 | 3.17 (m) | 72.8 |
| 5 | 4.60 (m) | 70.7 | 3.63 (m) | 68.8 |
| 6 | 1.55 (d, 6.4) | 19.1 | 1.08 (d, 6.0) | 18.2 |
| β-D-Xyl (at C-4 Rha-I) | | | | |
| 1 | 5.18 (d, 7.6) | 105.9 | 4.32 (d, 7.8) | 103.8 |
| 2 | 3.95 (m) | 75.7 | 2.88 (m) | 74.1 |
| 3 | 4.11 (m) | 78.6 | 3.13 (m) | 76.8 |
| 4 | 4.14 (m) | 71.6 | 3.23 (m) | 70.2 |
| 5 | 3.37 ^a | 67.6 | 3.68 ^a | 66.0 |
| | 4.15 (m) | | 2.94 (m) | |

^a Unclear signal pattern due to overlapping.

^b Compound 2 data reported in pyridine-*d*₅ (400/100 MHz).

^c Compound 3 data reported in DMSO-*d*₆ (600/150 MHz).

81.8), three upfield carbons including two methylene carbons (δ_C 31.9 & 39.9) and one methine carbon (δ_C 45.9). The provided data was found to be closely related to the reported data of the bioactive naturally occurring lignan cubebin (**1a**) (Vidigal et al., 1995; Macedo et al., 2020), except for the presence of an additional hydroxyl group. The placement

of this additional hydroxyl group was determined on the basis of ¹H-¹H COSY and HMBC experiments. In HMBC spectrum (Fig. S5) (Fig. 2), obvious correlations was found between CH₂-7 at δ_H 2.69 and δ_H 2.79 with C-1 (δ_C 132.0), C-2 (δ_C 110.9), C-6 (δ_C 123.5), C-8 (δ_C 81.8), C-9 (δ_C 102.8), between H-8' at δ_H 2.39 with C-1' (δ_C 134.9), C-7' (δ_C 31.9) and C-9' (δ_C 71.1), and between methylenic protons CH₂-9' at δ_H 3.53 and δ_H 3.70 with C-7' (δ_C 31.9), C-8 (δ_C 81.8), and C-8' (δ_C 45.9). Furthermore, the ¹H-¹H COSY spectrum (Fig. S6) (Fig. 2) showed correlations between H-7' (δ_H 2.37), H-8' (δ_H 2.39) and H-9' (δ_H 3.53 & 3.70). All the provided correlations recommend the placement of the hydroxyl group at position C-8.

X-ray crystallographic analysis was used to determine unequivocally the configuration of the hydroxyl group on C-8 and confirm the configuration of the asymmetric centres of **1**. A single crystal suitable for X-ray analysis was obtained by recrystallization of **1** from methanol solution. The crystallographic data confirmed the structure and revealed that the additional hydroxyl group attached to C-8, together with all asymmetric centres are of the *S* configuration (Fig. 3). The absolute configuration was determined from the Flack parameter (Parsons et al., 2013) $x = 0.14(18)$ based on 1017 quotients and from the Hooft parameter (Hooft et al., 2008) $y = 0.07(15)$ based on 1406 Bijvoet pairs (99% coverage), corresponding to a probability of 1.000 that the




Fig. 1. List of isolated compounds (1-5).




Fig. 2. Key ^1H - ^1H COSY and HMBC correlations in compound 1.

configuration is correct. Furthermore, the absence of cross peak correlation between H-9 and H-8' in NOESY spectrum (Fig. S7) confirms the difference in their spatial orientation. Accordingly, **1** was determined as 8 α -hydroxy cubebin and trivially named as Glandularin.

Compound **2**, a buff amorphous solid with the molecular formula $\text{C}_{58}\text{H}_{94}\text{O}_{25}$, gave a quasi-molecular ion peak at m/z 1189.5988 $[\text{M}-\text{H}]^-$ (calcd. for $\text{C}_{58}\text{H}_{93}\text{O}_{25}$, 1189.6006) in its negative mode HRESIMS spectrum, and a sodiated molecular ion peak at m/z 1213.6094 $[\text{M}+\text{Na}]^+$ (calcd. for $\text{C}_{58}\text{H}_{94}\text{O}_{25}\text{Na}$, 1213.5982) in its positive mode HRESIMS (Fig. S15 and S16). The IR spectrum of compound **2** showed characteristic bands of hydroxyl, ester, and glycosidic C–O at 3409, 2953, 1705, and 1055 cm^{-1} , respectively. The ^1H and ^{13}C -NMR spectra displayed signals characteristic for oleanane saponins derivative. The ^1H -NMR spectrum (Fig. S9) (Table 2) displayed seven singlet methyl peaks at δ_{H} 0.88, 1.01, 1.04, 1.12, 1.18, 1.31, 1.83 (each 3H, s), an axial proton attached to a hydroxylated carbon C-3 at δ_{H} 3.41 (dd, $J = 9.6, 3.2$ Hz), a methine proton attached to C-16 at δ_{H} 5.31 (br s) and an olefinic proton (H-12) at δ_{H} 5.65 (br s) indicated that it could be a Δ^{12} -16-hydroxyoleanene derivative. The combined spectral data of the aglycone part of **2** were in agreement with reported data of echinocystic acid (Figs. 1 and 4A) (Nagao et al., 1989; Jäger et al., 2017). The ^{13}C -NMR (Fig. S10) (Table 2) chemical shifts revealed the downfield shifting of C-3 and upfield shifting of C-28 suggesting the presence of two points of glycosidation, one at C-3 (δ_{C} 89.4) through an ether bridge, and the other esterifying the acid at carbonyl carbon C-28 (δ_{C} 176.5) of the aglycone. The length of the glycosidic ether-linked chain at position **3** of the aglycone was reduced to a single unit. It was identified as a β -D-glucose with its doublet anomeric proton at δ_{H} 4.95 (d, $J = 8.0$ Hz), which is correlated to its anomeric carbon (δ_{C} 107.4) in the HSQC experiment (Fig. S11). Proposition of the usual β -anomeric configuration for this sugar was based on the observation of the anomeric proton's large coupling constant value ($J = 8.0$ Hz). The attachment of the β -D-glucose moiety to C-3 was confirmed by the presence of correlations

between the anomeric proton (δ_{H} 4.95) with C-3 of the aglycone (δ_{C} 89.4), and vice versa between H-3 (δ_{H} 3.41) and the anomeric carbon (δ_{C} 107.4) in HMBC spectrum (Fig. S12) (Fig. 4B). Further investigation of NMR experiments allowed the detection of proton and carbon resonances of a tetrasaccharide chain composed of the most inner sugar arabinose, xylose, and two rhamnose moieties attached to C-28 (δ_{C} 176.5). The four anomeric protons for this chain were displayed at δ_{H} 5.18 (d, $J = 7.6$ Hz), 5.66 (br s), 5.86 (br s), and 6.56 (br s), bonded to carbons at δ_{C} 105.9, 101.9, 105.0, and 93.7, respectively, in the HSQC spectrum (Fig. S11). Among the four sugars (arabinose, rhamnose, and xylose), the ^1H -NMR data revealed that only xylose showed β -anomeric configuration, which was characterized by large trans-diaxial coupling constant value of its anomeric proton ($J = 7.6$ Hz), and the other two (arabinose and rhamnose) possess an α -configuration based on the scale of coupling constant values (all broad singlets) (Ishii et al., 1981; Lee et al., 2002; Jäger et al., 2017). The construction of the tetrasaccharide chain was completed using the cross peak correlations shown in ^1H - ^1H COSY, TOCSY and HMBC spectra (Fig. S12, S13 and S14) (Fig. 4B). In the HMBC spectrum (Fig. S12) (Fig. 4B), H-1 of Xyl (δ_{H} 5.18) was long-range coupled with C-4 (δ_{C} 77.9) of Rha-I, H-1 (δ_{H} 5.85) of Rha-II showed cross peak correlation with C-3 (δ_{C} 81.6) of Rha-I, also H-1 (δ_{H} 5.66) of Rha-I displayed correlation with C-2' (δ_{C} 76.3) of Ara, and H-1 (δ_{H} 6.56) of Ara was coupled with the carbonyl carbon of the aglycone C-28 (δ_{C} 176.5), which confirmed the sugar chain at C-28 to be β -D-xylopyranosyl-(1 \rightarrow 4)-[α -L-rhamnopyranosyl-(1 \rightarrow 3)]- α -L-rhamnopyranosyl-(1 \rightarrow 2)- α -L-arabinopyranosyl ester. According to the literature and NMR values of the reported analogues (Su et al., 2001; Lee et al., 2002; Eskander et al., 2005; Murata et al., 2013), **2** was determined as 3-O- β -D-glycopyranosyl-3 β ,16 α -dihydroxyolean-28-oic acid 28-O- β -D-xylopyranosyl-(1 \rightarrow 4)-[α -L-rhamnopyranosyl-(1 \rightarrow 3)]- α -L-rhamnopyranosyl-(1 \rightarrow 2)- α -L-arabinopyranosyl ester. To the best of our knowledge, this is the first report of this compound in nature.

Compound **3**, was obtained as a buff amorphous solid, its molecular formula $\text{C}_{63}\text{H}_{102}\text{O}_{29}$, was deduced from molecular ion peaks m/z 1345.6496 $[\text{M} + \text{Na}]^+$ (calcd for $\text{C}_{63}\text{H}_{102}\text{O}_{29}\text{Na}$, 1345.6404) in positive mode HRESIMS, and m/z 1357.6131 $[\text{M}+\text{Cl}]^-$ (calcd for $\text{C}_{63}\text{H}_{102}\text{O}_{29}\text{Cl}$, 1357.6127) in negative mode HRESIMS (Fig. S23 and S24), which was 132 mass unit more than **2**. The IR spectrum of compound **3** showed bands at 3398 (OH), 2910 (C–H), 1699 (C=O), 1051 (glycosidic C–O) cm^{-1} . The inspection of NMR data (Fig. S17–S22) of compound **3** revealed that ^1H and ^{13}C -NMR spectra displayed the same pattern of protons and carbons of the aglycone part and sugar chain attached to C-28 as in compound **2** (Table 2), recommending that an additional pentose sugar moiety attached to C-3 sugar chain. The ^1H -NMR data (Fig. S17) (Table 2) showed the anomeric proton of this additional sugar resonating at δ_{H} 5.28 and coupled with δ_{C} 109.4 in the HSQC spectrum (Fig. S19). In the ^1H - ^1H COSY experiment (Fig. S21) (Fig. 4C), the anomeric proton of the additional sugar moiety at δ_{H} 5.28 (d, $J = 2.4$ Hz) was observed to be coupled with a vicinal proton at δ_{H} 3.80, which appears also as a doublet (d, $J = 2.4$ Hz). This sugar was further characterized in the NMR spectra (Fig. S17 and S18) by two oxygenated methylene groups at δ_{C} 73.9 and 64.1, and an oxygenated quaternary carbon at δ_{C} 79.3. Analysis of 1D and 2D-NMR data showed that these findings were best arranged as a β -D-apiofuranosyl (Ishii and Yanagisawa, 1998; Farag et al., 2001; Eskander et al., 2005; Zhang et al., 2018). The sequence of the disaccharide sugar chain at C-3 of the aglycone was determined using HMBC spectrum (Fig. S20) (Fig. 4B); the cross peak correlations between H-1 of β -D-apiose (δ_{H} 5.28) with C-2 of Glu (δ_{C} 78.2) and H-1 of Glu (δ_{H} 4.23) with C-3 of aglycone (δ_{C} 88.7) (Lu and Yeap Foo, 2000). After reviewing literature (Eskander et al., 2005; Ragab et al., 2010; Meng et al., 2021), the complete structure of **3** was assigned as 3-O-(β -D-apiofuranosyl-(1 \rightarrow 2)- β -D-glucopyranosyl)-3 β ,16 α -dihydroxyolean-28-oic acid 28-O- β -D-xylopyranosyl-(1 \rightarrow 4)-[α -L-rhamnopyranosyl-(1 \rightarrow 3)]- α -L-rhamnopyranosyl-(1 \rightarrow 2)- α -L-arabinopyranosyl ester.




Fig. 3. Stereochemical structure of compound 1.

The UPLC-UV/MS method was used to characterise the monosaccharides in glycosidic compounds **2** and **3** to confirm their identities and absolute configurations. The hydrolysates of the isolated compounds, together with the monosaccharide's standards, were derivatized to diastereomeric arylthiocarbamates according to the reported procedures (Tanaka et al., 2007). The differentiation between the D- and L-configurations of each sugar was done by comparing its retention time to that of the standards. Derivatives of D-glucose (t_R 14.7 min), D-xylose (t_R 16.2 min), L-rhamnose (t_R 22.4 min), and L-arabinose (t_R 17.4 min) were identified as the sugar moieties of **2** and **3** based on comparisons with derivatives of authentic samples; D-glucose (t_R 14.7 min), L-glucose (t_R 13.3 min), D-xylose (t_R 16.2 min), L-xylose (t_R 14.8 min), L-rhamnose (t_R 22.4 min), D-arabinose (t_R 17.4 min), and L-arabinose (t_R 16.9 min) (Wang et al., 2012). The obtained mass spectra, on the other hand, were typical for pentoses (D-xylose and L-arabinose), hexoses (D-glucose) and deoxy hexoses (L-rhamnose), showing characteristic ions at m/z 403, 433, and 417, respectively (Wang et al., 2012). Therefore, from the obtained chromatograms and mass spectra, in addition to the published NMR data, the sugar moieties of compounds **2** and **3** were identified as

D-(+)-glucose, L(-)-rhamnose, D-(+)-xylose, and L(-)-arabinose.

Known compounds, **4** and **5** (Fig. 1), were characterized by comparing their spectral data with the NMR data of published analogues. These compounds were identified as adenosine (**4**) (Ciuffreda et al., 2007) and lamiide (**5**) (Güvenalp et al., 2006).

According to our earlier research, the chemotaxonomy of the genus *Glandularia* has been a subject of interest in order to aid in the establishment of the genus' phytochemical profile (Mohamed et al., 2020). We have previously reported the isolation of oleanane based triterpenoidal saponins as chemotaxonomic marker for genus *Glandularia* (Mohamed et al., 2020). In this study, we have also isolated one dibenzylbutyrolactolic lignan together with two echinocystic acid based triterpenoidal saponins, which have been detected for the first time in this genus. Hence, compounds **1–3** could be considered as valuable chemotaxonomic markers for genus *Glandularia* and confirm the unique identity of our plant under investigation.

2.2. Molecular docking

Modelling and docking simulations of the isolated compounds **1** and **2** were performed using Molecular Operating Environment (MOE) software ("Molecular Operating Environment (MOE) 2014.0901," n.d.) and the crystal structure of the murine inducible nitric oxide synthase iNOS; (PDB: 4UX6) (Cheshire et al., 2011).

The accuracy of MOE docking protocol was validated and confirmed by re-docking the co-crystallized ligand inside the active site of iNOS, where the docked ligand showed S score of -8.41 kcal/mol with RMSD 1.69 Å (Fig. S25). Also, in order to rationalize the biological results of isolated compounds, the docking study was performed and compared with the positive control; parthenolide (Fig. S26).

On the basis of docking score analysis against the protein target, the saponin structure (**2**) showed higher negative score (-9.59 kcal/mol)




Fig. 4. A) Key $^1\text{H}-^1\text{H}$ COSY and HMBC correlations of aglycone part of **2** and **3**. B) Key $^1\text{H}-^1\text{H}$ COSY and HMBC correlations of C-3 and C-28 sugar chains of **2**. C) Key $^1\text{H}-^1\text{H}$ COSY and HMBC correlations of C-3 and C-28 sugar chains of **3**.

than the lignan one (**1**) (−6.56 kcal/mol) which is compatible with the biological results. Binding mode analysis also revealed that both compounds bind snugly within the larger active-site cavity complexed with heme that coordinates to Cys194. The cavity gate is large enough to allow the diffusion of both compounds where the heme nearly closes the opposite surface. The sugar moiety at C-3 of the triterpenoid saponin structure resides in the main channel of the cavity over the heme structure forming three H-bond interactions with Glu371 (2.75 and 3.35 Å) and Gln 257 (3.03 Å). The sugar chain at the cavity opening stabilizes the complex by forming multiple H-bond interactions with Gln486 (3.01 Å), Glu488 (3.32 Å), Glu279 (3.35 and 3.24 Å), and Asn348 (3.00 Å) (Fig. 5B). Moreover, the hydrophobic aglycone reinforces the binding by forming hydrophobic interaction with Val346, Trp475, Met114, Ala276, and Pro344. Other ligand interactions within the active site include hydrophobic ones with Glu371, Gln257, Tyr485, Asn348, Ser256, Asn115, Gln381, Glu488, Glu279. Interestingly, docking of an assumed product of saponin structure, obtained via expected hydrolysis at the glycosidic ester bond, improved the overall binding profile of the compound. The retained sugar moiety at position C-3 of the hydrolyzed saponin structure accepts an additional H-bond from Tyr341 (3.25 Å), as well as the hydroxyl group at C-16 of the triterpenoid moiety donates a new H-bond to Ala276 (3.29 Å) at the cavity gate (Fig. 5C). On the other hand, the flexibility profile of compound **1** weakens its binding mode within the active site. The tetrahydrofuran moiety donates two H-bond interactions to Glu371 (2.78) and Asp376 (3.28) while accepting one H-bond from Gln257 (3.12). However, one of the benzodioxol moieties of compound **1** is located inside the main channel of the cavity and slightly stacks with the heme structure, while the other one fluctuates to the gate (Fig. 5A). Docking results revealed that the dioxol group in the structure of compound **1**, rather than dihydroxy, on both sides of the tetrahydrofuran moiety increases the chance for the compound flexibility and in turn decreasing its probability of forming H-bond interactions deep inside the active site (Fig. S27 and S28).

To conclude, molecular docking study supported the biological data of the isolated compounds and proposed a mechanism for the anti-inflammatory activity of the saponin (compound **2**) via acting as competitive inhibitor for the substrate; L-arginine at its binding site within iNOS.

2.3. Prediction of pharmacokinetic properties (ADMET)

The ADMET properties of compounds **1** and **2** as well as the assumed hydrolysate of compound **2** under docking study were calculated using the pkCSM-pharmacokinetics server (<http://biosig.unimelb.edu.au/pkcsm/>) by providing SMILES (Simplified Molecule Input Line Entry Specification) of the compounds generated by ChemDraw software. Physicochemical properties of compounds **1** and **2**, together with hydrolysate of compound **2** are listed in Table 3.

The efficacy of any compound as an orally active drug was determined using Caco2 permeability and intestinal absorption models. Only compound **1** which obeys lipinski's rules of five shows the Caco2 permeability value in positive integer and demonstrates its intestinal absorption ability with 96%, while compound **2** is considered to be very poorly absorbed from the human intestine. However, hydrolysate of compound **2** demonstrates better intestinal absorption by 38%, which considered as reasonable absorption, upon lack of the sugar chain at C-28 of the hydrolyzed saponin structure. Upon reaching the colonic tract, saponins were reported to be hydrolysed mainly via the action of the microbiota (Navarro del Hierro et al., 2018). The next important variable in absorption is skin permeability, and all compounds have permeability values of less than $-2.5 \log K_p$, suggesting poor permeability. P-glycoprotein is a component of the ATP-binding cassette (ABC) transporter, which is required for active molecular transport across cell membranes. Only compound **2** and its predicted hydrolysate were discovered to be P-glycoprotein substrates, suggesting that they can move through the cell membrane via the ABC transporter. Besides this,




Fig. 5. A) 3D-docked model of compound **1** within the active site of iNOS; heme was shown in dark pink co-ordinating with amino acid residue; Cys194, (shown in dark cyan). B) 3D-docked model of compound **2** within the active site of iNOS; heme was shown in dark pink co-ordinating with amino acid residue; Cys194, (shown in dark cyan). C) 3D-docked model of hydrolysate of compound **2** within the active site of iNOS; heme was shown in dark pink co-ordinating with amino acid residue; Cys194, (shown in dark cyan).

compounds **1** and **2** were found to be effective as inhibitors for P-glycoprotein I transporters and ineffective as inhibitors for P-glycoprotein II transporters. On the other hand, hydrolysate of compound **2** was discovered to be ineffective in both cases, implying that it is unable to inhibit both of these drug efflux pumps. The VDss assay is used to measure the total amount of drug required for uniform drug distribution in the blood. However, both compounds showed low VDss values

Table 3Physicochemical properties of compounds **1**, **2** and the suggested hydrolysate of compound **2**

| Descriptor | Compounds | | |
|------------------|-----------|----------|---------------------------|
| | 1 | 2 | Hydrolysate of compound 2 |
| Molecular Weight | 372.373 | 1191.365 | 634.851 |
| LogP | 1.6251 | -1.9069 | 4.0286 |
| #Rotatable Bonds | 4 | 11 | 4 |
| #Acceptors | 7 | 25 | 8 |
| #Donors | 2 | 14 | 6 |
| Surface Area | 155.547 | 483.209 | 267.942 |

indicating slow diffusion in blood. The permeability of the Blood-Brain Barrier (BBB) determines a compound's ability to move to the brain. They will be poorly distributed to the brain if the logBB values are less than -1. Only compound **1** would be able to cross BBB. However, the blood brain permeability surface area product (logPS) is a more direct and accurate measurement. All compounds with logPS < -3 are considered unable to penetrate the CNS. Predicted metabolism of the compounds in the body was assessed using seven different cytochrome models. Compound **1** is likely to be metabolized by CYP3A4 and also going to be a CYP1A2 and CYP3A4 inhibitor. On the other hand, compound **2** is neither a substrate nor an inhibitor for cytochrome P450.

All compounds had different total clearance rates, and only compound **2** appeared as a substrate for organic cation transporter 2 (OCT2). Furthermore, none of them predicted AMES toxicity, suggesting that these compounds are neither carcinogenic nor mutagenic. Skin sensitisation and hepatotoxicity were not seen in any of the compounds. The toxic effects of compounds are shown in Table 4 along with other ADMET properties.

2.4. Inhibition of iNOS activity

Nitric oxide (NO) is one of the main inflammatory mediators involved in both inflammation and angiogenesis processes. The

production of NO depends on cytokine-induced expression of inducible nitric oxide synthase (iNOS) (Cassini-Vieira et al., 2015). It is produced *in vivo* from the natural substrate; L-arginine and oxygen by either endothelial (eNOS), neuronal (nNOS) and inducible nitric oxide synthase (iNOS) (Fischmann et al., 1999; Subedi et al., 2021). During rheumatoid arthritis and asthma, cytokines induce prolonged and over-production of NO merely by iNOS which may result in increased cytotoxicity (Cheshire et al., 2011). Hence, iNOS is a primary mediator of inflammation and many drugs nowadays are targeting inhibition of iNOS to reduce inflammation process and adverse effects associated with it (Green et al., 1994). Some naturally occurring saponins and lignans were found to down-regulate NO production induced by inflammatory mediators (Navarro et al., 2018; He et al., 2019). Compounds **1-3** were tested for their anti-inflammatory activity through the inhibition of iNOS mediator. Compound **1** exhibited moderate inhibition activity on iNOS with IC₅₀ value of 49.7 μM, while compound **2** showed relatively significant activity with IC₅₀ value of 6.6 μM. The obtained results were compared to parthenolide, the positive control, which showed IC₅₀ value of 1.2 μM. All results are listed in Table 5.

Table 5Inhibition of iNOS activity of the isolated compounds **1-3**.

| Compound no. | Inhibition of iNOS | % cell death at 25 μg/mL |
|---------------------------|-----------------------------|--------------------------|
| | IC ₅₀ μM (μg/mL) | |
| 1 | 49.7 (18.5) | 62 |
| 2 | 6.6 (7.9) | 86 |
| 3 | ^a NA | ^a NA |
| ^b Parthenolide | 1.2 (0.29) | 94 |

^a NA, not active.^b Positive control.**Table 4**ADMET properties of compounds **1**, **2** and the suggested hydrolysate of compound **2**

| Property | Model Name | Predicted Values of compounds | | | Unit |
|----------------------|-----------------------------------|-------------------------------|--------|--------------------------|-------------------------------|
| | | 1 | 2 | Hydrolyste of compound 2 | |
| Absorption | Water solubility | -3.347 | -2.886 | -3.363 | Numeric (log mol/L) |
| | Caco2 permeability | 1.199 | -0.754 | -0.331 | Numeric (log Papp in 10 cm/s) |
| | Intestinal absorption (human) | 96.372 | 1.871 | 38.181 | Numeric (% Absorbed) |
| | Skin Permeability | -2.752 | -2.735 | -2.735 | Numeric (log Kp) |
| | P-glycoprotein substrate | No | Yes | Yes | Categorical (Yes/No) |
| | P-glycoprotein I inhibitor | Yes | Yes | No | Categorical (Yes/No) |
| Distribution | P-glycoprotein II inhibitor | No | No | No | Categorical (Yes/No) |
| | VDss (human) | -0.164 | -0.194 | -0.968 | Numeric (log L/kg) |
| | Fraction unbound (human) | 0.048 | 0.378 | 0.182 | Numeric (Fu) |
| | BBB permeability | -0.658 | -3.453 | -1.64 | Numeric (log BB) |
| Metabolism | CNS permeability | -3.36 | -5.464 | -2.876 | Numeric (log PS) |
| | CYP2D6 substrate | No | No | No | Categorical (Yes/No) |
| | CYP3A4 substrate | Yes | No | Yes | Categorical (Yes/No) |
| | CYP1A2 inhibitor | Yes | No | No | Categorical (Yes/No) |
| | CYP2C19 inhibitor | Yes | No | No | Categorical (Yes/No) |
| | CYP2C9 inhibitor | No | No | No | Categorical (Yes/No) |
| | CYP2D6 inhibitor | No | No | No | Categorical (Yes/No) |
| | CYP3A4 inhibitor | Yes | No | No | Categorical (Yes/No) |
| Excretion | Total Clearance | 0.046 | -0.111 | -0.003 | Numeric (log ml/min/kg) |
| | Renal OCT2 substrate | No | Yes | No | Categorical (Yes/No) |
| Toxicity | AMES toxicity | No | No | No | Categorical (Yes/No) |
| | Max. tolerated dose (human) | -0.217 | 0.14 | -0.466 | Numeric (log mg/kg/day) |
| | hERG I inhibitor | No | No | No | Categorical (Yes/No) |
| | hERG II inhibitor | No | Yes | No | Categorical (Yes/No) |
| | Oral Rat Acute Toxicity (LD50) | 2.494 | 2.482 | 2.75 | Numeric (mol/kg) |
| | Oral Rat Chronic Toxicity (LOAEL) | 1.611 | 8.228 | 4.482 | Numeric (log mg/kg_bw/day) |
| | Hepatotoxicity | No | No | No | Categorical (Yes/No) |
| | Skin Sensitisation | No | No | No | Categorical (Yes/No) |
| T.Pyiformis toxicity | 0.305 | 0.285 | 0.285 | Numeric (log ug/L) | |
| Minnow toxicity | -0.054 | 17.28 | 3.583 | Numeric (log mM) | |

2.5. Cytotoxic activity of isolated compounds

The cytotoxic activity of compounds 1–3 was investigated using an *in vitro* assay against a series of human solid tumor cells including SK-MEL (malignant melanoma), KB (oral epidermal carcinoma), BT-549 (breast ductal carcinoma), SK-OV-3 (ovary carcinoma), and LLC-PK1 (renal epithelial cells). Their cytotoxicity was also determined against noncancerous mammalian VERO cells (renal fibroblast) for comparison. The cytotoxic potencies of these compounds are expressed in terms of IC₅₀ values, as shown in Table 6. Compound 1 showed moderate cytotoxic activity against SK-MEL with IC₅₀ value of 45.6 μM, in addition to cytotoxic activity against VERO cells with IC₅₀ value of 37.6 μM, indicating the un-selectivity to tumor cells. To the best of our knowledge, cubebin (1a), and its synthetic derivatives with varying functional moieties, showed significant anticancer activity upon testing against six human cancer cell lines (A549, K562, SiHa, KB, HCT116 and HT29) using MTT assay (Rajalekshmi et al., 2016). Compound 2 showed relatively potent cytotoxic activity against all the tested cell lines with IC₅₀ values ranging between <5.3 and 10.1 μM. Compound 3 showed moderate cytotoxic activity against KB, BT-549, SK-OV-3, and renal epithelial cells with IC₅₀ values ranging between 8.3 and 18.9 μM. All the results were compared to doxorubicin which was used as positive control with IC₅₀ values ranging between 2.6 and 9.2 μM.

3. Conclusions

Three previously undescribed compounds (1–3) and two known compounds (4–5) were isolated from the leaves of *G. hybrida*. Their structures were determined by NMR and HRESIMS data analysis. Additionally, *in silico* and *in vitro* assessments of some biological activities for compounds 1–3 revealed that these compounds could be considered as promising cytotoxic agents and inhibitors of iNOS mediator.

4. Experimental section

4.1. General experimental procedures

Optical rotations were recorded at room temperature using a Rudolph AutoPol IV automatic polarimeter (Rudolph Research Analytical, Hackettstown, NJ, USA); UV spectra were recorded by a Hewlett-Packard 8452 A UV-Vis spectrometer (American Laboratory Trading, CT, USA); IR spectra were acquired using Bruker Tensor 27 and MIRacle ATR FT-IR spectrometers (Bruker Scientific Instruments, Bruker Optics, MA, USA); 1D and 2D NMR spectra were recorded in DMSO-*d*₆ or pyridine-*d*₅ and acquired on Bruker Avance DRX spectrometer at 400 MHz (¹H) and 100 MHz (¹³C), 600 MHz (¹H) and 150 MHz (¹³C). The chemical shifts are given in δ (ppm) and were calibrated using the residual solvent signals; coupling constants (*J*) are reported in Hertz (Hz). The signals in the spectra are described as s (singlet), d (doublet), t

Table 6
Cytotoxicity of the isolated compounds 1–3.

| Compounds | IC ₅₀ μM (μg/mL) | | | | | |
|--------------------------|-----------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | SK-MEL | KB | BT-549 | SK-OV-3 | LLC-PK1 | VERO |
| 1 | 45.6 (17) | ^b NA | ^b NA | ^b NA | ^b NA | 37.6 (14) |
| 2 | <5.3 | 9.2 | 10.1 | 10.1 | 8.4 | <5.3 |
| | (<6.25) | (11) | (12) | (12) | (10) | (<6.25) |
| 3 | ^b NA | 13.5 | 15.0 | 8.3 | 18.9 | ^b NA |
| | | (18) | (20) | (11) | (25) | |
| ^c Doxorubicin | 2.8 (1.5) | 2.9 | 3.1 | 2.6 | 2.6 | 9.2 (5) |
| | | (1.6) | (1.7) | (1.4) | (1.4) | |

^a The highest concentration tested was 25 μg/mL.

^b NA, not active.

^c Positive control

(triplet), m (multiplet) and br (broad resonances). High-resolution mass spectra were recorded using a HRESI-TOFMS spectrometer (Agilent Series 1100 SL, ESI source model #G1969A, Agilent Technologies, Palo Alto, CA, USA). Solvents used for extraction and isolation purposes were analytical grade (Fisher Scientific, Fair Lawn, NJ, USA). Column chromatography was carried out using silica gel 60 F₂₅₄ (40–65 μm, Merck, Darmstadt, Germany), Sephadex LH-20 (0.25–0.1 mm, Mitsubishi Kagaku, Tokyo, Japan), and reversed-phase C₁₈ silica gel (Polarbond, JT Baker). TLC was performed on silica 60 F₂₅₄ (0.2 mm, Merck, Darmstadt, Germany) pre-coated aluminum sheets. Visualization of spots was done by spraying with 5% vanillin (Sigma-Aldrich) solution in conc. H₂SO₄-EtOH (5:95) followed by heating.

4.2. Plant material

During the flowering stage, the fresh leaves of *G. × hybrida* (Groenl. & Rümpler) G.L. Nesom & Pruski (unresolved name: see The Plant List <http://www.theplantlist.org>) (Verbenaceae) were collected on April–May 2013 from Hebat El Nile nurseries, El-Manial, Cairo, Egypt, at geographical coordinates 30° 01' 08" N 31° 13' 02" E and an altitude of 20 m. The identity of the selected species was authenticated by (the late) Prof. N. E. Keltawy, Professor of Ornamental Horticulture and Floriculture, Faculty of Agriculture, Assiut University, Assiut, Egypt. A voucher specimen number GHV-2013 was recorded and lodged at the Herbarium of Pharmacognosy Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt.

4.3. Extraction and isolation

The air dried leaves (4 kg) were ground and extracted at room temperature in 70% (v/v) aqueous ethanol (4 × 6 L). The obtained extract was decanted, filtered, and combined extracts were concentrated using rotary evaporator with a water bath of 40 °C, to get a concentrated extract (284 g). The obtained extract was suspended in distilled water (250 mL) and defatted by liquid-liquid partition using *n*-hexane solvent. The remaining aqueous extract was collected and concentrated under reduced pressure to get defatted residue (170 g). About 70 g of the defatted extract was fractionated on vacuum liquid chromatography (VLC) using C-18-reversed phase silica gel (80 × 7.0 cm, 500 g) as stationary phase, and by increasing MeOH in MeOH-H₂O system (1 L 0%, 1.5 L 20%, 2 L 40%, 2 L 60%, 2 L 80% and 2 L 100%) with the collection of 300 mL fractions. The fractions were collected based on their TLC profile resulting in six main fractions (GH-I:GH-VI). TLC analysis of obtained fractions recommended the presence of promising compounds in fractions GH-II (5.3 g), GH-III (7.1 g) and GH-V (6.3 g). About 1 g of fraction GH-II was subjected to column chromatography (CC) using sephadex LH-20 as stationary phase (150 × 2.3 cm, 150 g) and MeOH as eluent (500 mL) to yield compounds 5 (5.3 mg) and 4 (7.6 mg), respectively. A part of fraction GH-III (1 g) was further separated on sephadex LH-20 CC (150 × 2.3 cm, 150 g), using MeOH (500 mL) as eluent to get three subfractions GH-III-1 to GH-III-3. Subfraction GH-III-1 (253 mg) was further purified on silica gel CC, using system EtOAc-CH₂Cl₂-MeOH-H₂O with gradient elution program [10:6:5:1.25 & 6:4:5:1.25, (250 mL)] to afford compounds 2 (15.4 mg) and 3 (10.8 mg), respectively. About 1.7 g of fraction GH-V was subjected to silica gel CC (100 × 1.5 cm, 80 g) using CH₂Cl₂-MeOH [95:5, (500 mL)], to get subfraction GH-V-1 (273 mg), which was further purified on silica gel CC (80 × 1 cm, 25 g) using EtOAc-CH₂Cl₂-MeOH-H₂O as eluent in isocratic elution manner [17:10:4:1, (250 mL)] to isolate compound 1 (7.3 mg).

4.4. Determination of absolute configuration of sugar

The determination of the composition of sugar moieties and their configuration was performed according to UPLC-UV/MS method (Wang et al., 2012). Compounds 2 and 3 were acid hydrolyzed by dissolving

about 1 mg of each compound in 1 mL of 2N HCl. The dissolved samples were heated in a water bath to 95 °C for 1 h. After hydrolysis, the reaction mixture was chilled, treated with liquid ammonia, and completely dried with N₂ gas. Monosaccharide standards together with the hydrolysates of **2** and **3** were derivatized (Tanaka et al., 2007; Wang et al., 2012). The final derivatives were analysed by UPLCTM BEH C-18 column (100 mm × 2.1 mm), with particle size 1.7 μm; mobile phase, 0.05% formic acid in water (A) and acetonitrile/methanol/isopropanol (50:25:25, v/v/v) with 0.05% formic acid (B), flow rate of the mobile phase was set at 0.3 mL/min; PDA detector, UV at 254 nm. The column temperature were maintained at 35 °C. The experiment was carried out in gradient elution manner: starting with system 14% B to 16.5% B in 22 min, and then increasing B to 100% in the subsequent 0.5 min. The ESI source of single quadrupole mass spectrometer (SQD) was adjusted to positive mode. The configurations of the sugar units were determined through comparing retention times and mass spectra with that of the used reference standards (Wang et al., 2012). The standard monosaccharides included: D-(+)-glucose, L-(-)-glucose, L-(-)-rhamnose, D-(+)-xylose, L-(-)-xylose, L-(-)-arabinose and D-(+)-arabinose.

4.5. X-ray experimental

Intensity data were collected at 90 K to $\theta_{\max} = 69.2^\circ$ on a Bruker Kappa Apex-II diffractometer with CuK α radiation. Absorption corrections were done by the multi-scan method. Refinement was done by SHELXL-2018. Hydrogen atoms were visible in difference maps, and were placed in idealized positions, except for those on O, for which positions were refined. The Flack parameter 0.14 (18) is in agreement with the absolute configuration of (-)-cubebin. Crystal Data: monoclinic space group P2₁, a = 11.5470 (4), b = 5.5768 (2), c = 13.4963 (5) Å, $\beta = 100.029 (3)^\circ$, 13,377 reflections collected, 3180 unique, 2677 with $I > 2\sigma(I)$, R = 0.049 for 250 parameters, CCDC 2057610.

4.6. Spectroscopic data of compounds (1–3)

4.6.1. Glandularin (1)

Colourless residue; $[\alpha]_D^{20} -19$ (c 0.1, MeOH); UV (MeOH) λ_{\max} 281 and 228 nm; ¹H and ¹³C-NMR data (DMSO-*d*₆, 400/100 MHz), see Table 1; HRESIMS *m/z* 371.1176 [M-H]⁻ (calcd. for C₂₀H₁₉O₇, 371.1131), *m/z* 417.1219 [M + HCOO]⁻ (calcd. for C₂₁H₂₁O₉ 417.1191) negative mode.

4.6.2. 3-O-β-D-glycopyranosyl-3β,16α-dihydroxyolean-28-oic acid 28-O-β-D-xylopyranosyl-(1→4)-[α-L-rhamnopyranosyl-(1→3)]-α-L-rhamnopyranosyl-(1→2)-α-L-arabinopyranosyl ester (2)

Buff amorphous solid; $[\alpha]_D^{20} -120$ (c 0.1, MeOH); IR (KBr) ν_{\max} 3409, 2953, 1705, 1683, 1370, 1055 cm⁻¹; UV (MeOH) λ_{\max} 202 nm; ¹H and ¹³C-NMR data (Pyridine-*d*₅, 400/100 MHz), see Table 2; HRESIMS *m/z* 1189.5988 [M-H]⁻ (calcd. for C₅₈H₉₃O₂₅, 1189.6006) negative mode, *m/z* 1213.6094 [M+Na]⁺ (calcd. for C₅₈H₉₄O₂₅Na, 1213.5982) positive mode.

4.6.3. 3-O-(β-D-apiofuranosyl-(1→2)-β-D-glucopyranosyl)-3β,16α-dihydroxyolean-28-oic acid 28-O-β-D-xylopyranosyl-(1→4)-[α-L-rhamnopyranosyl-(1→3)]-α-L-rhamnopyranosyl-(1→2)-α-L-arabinopyranosyl ester (3)

Buff amorphous solid; $[\alpha]_D^{20} -100$ (c 0.1, MeOH); IR (KBr) ν_{\max} 3398, 2910, 1699, 1630, 1373, 1051 cm⁻¹; UV (MeOH) λ_{\max} 203 nm; ¹H and ¹³C-NMR data (DMSO-*d*₆, 600/150 MHz), see Table 2; HRESIMS *m/z* 1345.6496 [M+Na]⁺ (calcd for C₆₃H₁₀₂O₂₉Na, 1345.6404) positive mode, *m/z* 1357.6131 [M+Cl]⁻ (calcd for C₆₃H₁₀₂O₂₉Cl, 1357.6127) negative mode.

4.7. Molecular docking

The molecular modelling calculations and docking simulation

studies were performed on a Processor Intel(R) Pentium(R) CPU N3510@ 1.99 GHz and 4 GB Memory with Microsoft Windows 8.1 pro (64 Bit) operating system using Molecular Operating Environment (MOE 2019.0102, 2020; Chemical Computing Group, Canada) as the computational software. All MOE minimizations were performed until a RMSD gradient of 0.01 kcal/mol/Å with the force field (MMFF94x) to calculate the partial charges automatically using Gas phase solvation. Before simulations, the protein was protonated using LigX function and the monomer was isolated. Triangle matching with London dG scoring was chosen for initial placement, and then the top 30 poses were refined using force field (MMFF94x) and GBVI/WSA dG scoring. The output database dock file was created with different poses for each ligand and arranged according to the final score function (S), which is the score of the last stage that was not set to zero.

4.8. Biological activity evaluations

4.8.1. Assay for the inhibition of iNOS activity

Mouse macrophages (RAW264.7) were used in this assay, which were grown in RPMI media supplemented with 10% bovine calf serum, 100 g/mL streptomycin, and 100 U/mL penicillin G sodium. Cells were implanted in 96-well plates (100,000 cells/well) and incubated for 24 h until they reach 75% or higher confluence.

The cells were exposed to the test compounds (1–3), then after 30 min, LPS (Sigma-Aldrich) (5 μg/mL) was added and cells were further incubated for 24 h. The concentration of NO was done by estimation of the level of nitrite in the supernatant of the cell culture using Griess reagent (Sigma-Aldrich). This was considered as an indication for the iNOS activity. Inhibition of iNOS activity achieved by the test compound was calculated in comparison to the negative control. Dose-response curves were used to determine the IC₅₀ values. Parthenolide was included as drug control. (Zhao et al., 2014; Zulfiqar et al., 2017).

4.8.2. Assay for cytotoxic activity

The cytotoxic activity of the isolated compounds (1–3) was determined by a cell proliferation assay against a panel of human cancer cell lines (SK-MEL, KB, BT-549, SK-OV-3, LLC-PK1), as well as VERO cell line (renal fibroblast). Cell lines have been obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cells were seeded in 96-well plates at a density of 10,000 cells/well and incubated for 24 h. Test samples at various dilutions were added and the cells were further incubated for 48 h. The cell viability was determined by using a tetrazolium dye (WST-8) which is converted to a water soluble formazan product in the presence of 1-methoxy PMS by the activity of cellular dehydrogenases. The amount of resulting formazan was measured by reading the absorbance at $\lambda = 450$ nm which is directly proportional to the number of viable cells. The viability of sample treated cells was calculated in comparison to the vehicle treated cells and the concentration responsible for decreasing 50% cell viability (IC₅₀ value) was calculated from the concentration response curves. Doxorubicin was included as the positive control for cytotoxicity assay (Zulfiqar et al., 2017).

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

This research was supported financially by the Egyptian Government and the National Centre of Natural Products Research (NCNPR), School of Pharmacy, University of Mississippi, USA. Research reported in this publication was also supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the

National Institutes of Health under award number P20GM130460. We are thankful to Dr. Bahartha Avula for providing HRESIMS.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.phytochem.2021.113054>.

References

- Ahmed, M.A.M., Mohamed, N.M., Woodman, T.J., Kociok-Köhn, G., Blagbrough, I.S., 2021. Loganin-type iridoids as chemotaxonomic markers in *Glandularia goodingii* (Briq.) Solbrig. *Phytochem. Lett.* 44, 68–73. <https://doi.org/10.1016/j.phytochem.2021.04.003>.
- Cassini-Vieira, P., Araújo, F.A., Da Costa Dias, F.L., Russo, R.C., Andrade, S.P., Teixeira, M.M., Barcelos, L.S., 2015. iNOS activity modulates inflammation, angiogenesis, and tissue fibrosis in polyether-polyurethane synthetic implants. *Mediat. Inflamm.* <https://doi.org/10.1155/2015/138461>, 2015.
- Cheshire, D.R., Åberg, A., Andersson, G.M.K., Andrews, G., Beaton, H.G., Birkinshaw, T. N., Boughton-Smith, N., Connolly, S., Cook, T.R., Cooper, A., Cooper, S.L., Cox, D., Dixon, J., Gensmantel, N., Hamley, P.J., Harrison, R., Hartopp, P., Käck, H., Leeson, P.D., Luker, T., Mete, A., Millichip, I., Nicholls, D.J., Pimm, A.D., St-Gallay, S.A., Wallace, A.V., 2011. The discovery of novel, potent and highly selective inhibitors of inducible nitric oxide synthase (iNOS). *Bioorg. Med. Chem. Lett.* 21, 2468–2471. <https://doi.org/10.1016/j.bmcl.2011.02.061>.
- Ciuffreda, P., Casati, S., Manzocchi, A., 2007. Complete ¹H and ¹³C-NMR spectral assignment of alpha- and beta-adenosine, 2'-deoxyadenosine and their acetate derivatives. *Magn. Reson. Chem.* 45, 781–784. <https://doi.org/10.1002/mrc>.
- Eskander, J., Lavaud, C., Abdel-khalik, S.M., Soliman, H.S.M., Mahmoud, I.L., Long, C., 2005. Saponins from the leaves of *Mimusops laurifolia*. *J. Nat. Prod.* 68, 832–841. <https://doi.org/10.1021/np049582e>.
- Farag, S.F., Ahmed, A.S., Terashima, K., Takaya, Y., Niwa, M., 2001. Isoflavonoid glycosides from *Dalbergia sissoo*. *Phytochemistry* 57, 1263–1268. [https://doi.org/10.1016/S0031-9422\(01\)00195-9](https://doi.org/10.1016/S0031-9422(01)00195-9).
- Fischmann, T.O., Hruza, A., Niu, X. Da, Fossetta, J.D., Lunn, C.A., Dolphin, E., Prongay, A.J., Reichert, P., Lundell, D.J., Narula, S.K., Weber, P.C., 1999. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. *Nat. Struct. Biol.* 6, 233–242. <https://doi.org/10.1038/6675>.
- Green, S.J., Scheller, L.F., Marletta, M.A., Seguin, M.C., Klotz, F.W., Slayter, M., Nelson, B.J., Nacy, C.A., 1994. Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens. *Immunol. Lett.* 43, 87–94. [https://doi.org/10.1016/0165-2478\(94\)00158-8](https://doi.org/10.1016/0165-2478(94)00158-8).
- Güvenalp, Z., Özbek, H., Ünsalar, T., Kazaz, C., Demirezer, L.Ö., 2006. Iridoid, flavonoid, and phenylethanoid glycosides from *Wiedemannia orientalis*. *Turk. J. Chem.* 30, 391–400.
- He, Y., Hu, Z., Li, A., Zhu, Z., Yang, N., Ying, Z., He, J., Wang, C., Yin, S., Cheng, S., 2019. Recent advances in biotransformation of saponins. *Molecules* 24, 2365. <https://doi.org/10.3390/molecules24132365>.
- Hoof, R.W.W., Straver, L.H., Spek, A.L., 2008. Determination of absolute structure using Bayesian statistics on Bijvoet differences. *J. Appl. Crystallogr.* 41, 96–103. <https://doi.org/10.1107/S0021889807059870>.
- Ishii, H., Kitagawa, I., Matsushita, K., Shirakawa, K., Tori, K., 1981. The configuration and conformation of the arabinose moiety in Platycodins, saponins isolated from *Platycodon grandiflorum*, and MI-saponins from *Mahuca longifolia* based on ¹³C- and ¹H-NMR spectroscopic evidence: the total structures of the sa. *Tetrahedron Lett.* 22, 1529–1532.
- Ishii, T., Yanagisawa, M., 1998. Synthesis, separation and NMR spectral analysis of methyl apiofuranosides. *Carbohydr. Res.* 313, 189–192. [https://doi.org/10.1016/S0008-6215\(98\)00262-6](https://doi.org/10.1016/S0008-6215(98)00262-6).
- Jæger, D., Ndi, C.P., Crocoll, C., Simpson, B.S., Khakimov, B., Guzman-Genuino, R.M., Hayball, J.D., Xing, X., Bulone, V., Weinstein, P., Møller, B.L., Semple, S.J., 2017. Isolation and structural characterization of echinocystic acid triterpenoid saponins from the Australian medicinal and food plant *Acacia ligulata*. *J. Nat. Prod.* 80, 2692–2698. <https://doi.org/10.1021/acs.jnatprod.7b00437>.
- Lee, K.T., Choi, J., Jung, W.T., Nam, J.H., Jung, H.J., Park, H.J., 2002. Structure of a new echinocystic acid bisdesmoside isolated from *Codonopsis lanceolata* roots and the cytotoxic activity of prosapogenins. *J. Agric. Food Chem.* 50, 4190–4193. <https://doi.org/10.1021/jf0116471>.
- Lu, Y., Yeap Foo, L., 2000. Flavonoid and phenolic glycosides from *Salvia officinalis*. *Phytochemistry* 55, 263–267. [https://doi.org/10.1016/S0031-9422\(00\)00309-5](https://doi.org/10.1016/S0031-9422(00)00309-5).
- Mabberley, D.J., 2017. *Mabberley's Plant-Book*, Mabberley's Plant-Book. Cambridge University Press. <https://doi.org/10.1017/9781316335581>.
- Macedo, A.L., Martorano, L.H., de Albuquerque, A.C.F., Fiorot, R.G., Carneiro, J.W.M., Campos, V.R., Vasconcelos, T.R.A., Valverde, A.L., Moreira, D.L., dos Santos, F.M., 2020. Absolute configuration of (–)-cubebin, a classical lignan with pharmacological potential, defined by means of chiroptical spectroscopy. *J. Braz. Chem. Soc.* 31, 2030–2037. <https://doi.org/10.21577/0103-5053.20200103>.
- Meng, Y., Feng, Z.M., Jiang, J.S., Zhang, X., Zhang, P.C., Yang, Y.N., 2021. Three new monocyclic monoterpene O-glycosides from the roots of *Glycyrrhiza uralensis*. *J. Asian Nat. Prod. Res.* 23, 318–324. <https://doi.org/10.1080/10286020.2020.1845162>.
- Mohamed, N.M., Makkoul, M.A., Farag, S.F., Wang, Y.H., Mohamed, S.M., Ross, S.A., 2020. Chemosystematically valuable triterpenoid saponins from *Glandularia x hybrida*. *Phytochemistry* 175, 112367. <https://doi.org/10.1016/j.phytochem.2020.112367>.
- Molecular Operating Environment, 2014. 0901. n.d (MOE).
- Murata, T., Suzuki, A., Mafune, N., Sato, E., Miyase, T., Yoshizaki, F., 2013. Triterpene saponins from *Clethra barbinervis* and their hyaluronidase inhibitory activities. *Chem. Pharm. Bull.* 61, 134–143. <https://doi.org/10.1248/cpb.c12-00566>.
- Nagao, T., Hachiyama, S., Okabe, H., Yamauchi, T., 1989. Studies on the constituents of *Aster tataricus* L.f. II. Structures of aster saponins isolated from the root. *Chem. Pharm. Bull.* 37, 1977. <https://doi.org/10.1248/cpb.37.1977>, 1983.
- Navarro del Hierro, J., Herrera, T., Fornari, T., Reglero, G., Martin, D., 2018. The gastrointestinal behavior of saponins and its significance for their bioavailability and bioactivities. *J. Funct. Foods* 40, 484–497. <https://doi.org/10.1016/j.jff.2017.11.032>.
- O'Leary, N., Thode, V., 2016. The genus *Glandularia* (verbenaceae) in Brazil. *Ann. Mo. Bot. Gard.* 101, 699–749. <https://doi.org/10.3417/2014008>.
- Parsons, S., Flack, H.D., Wagner, T., 2013. Use of intensity quotients and differences in absolute structure refinement. *Acta Crystallogr. Sect. B Struct. Sci. Cryst. Eng. Mater.* 69, 249–259. <https://doi.org/10.1107/S2052519213010014>.
- Pruski, J.F., Nesom, G.L., 1992. *Glandularia x hybrida* (Verbenaceae), a new combination for a common horticultural plant. *Brittonia* 44, 494–496. <https://doi.org/10.2307/2807200>.
- Ragab, E.A., Hosny, M., Kadry, H.A., Ammar, H.A., 2010. Acylated triterpenoidal saponins and cytokinins from *Gleditsia aquatica*. *J. Pharmacogn. Phyther.* 2, 24–33.
- Rajalekshmi, D.S., Kabeer, F.A., Madhusoodhanan, A.R., Bahulayan, A.K., Prathapan, R., Prakasan, N., Varughese, S., Nair, M.S., 2016. Anticancer activity studies of cubebin isolated from *Piper cubeba* and its synthetic derivatives. *Bioorg. Med. Chem. Lett.* 26, 1767–1771. <https://doi.org/10.1016/j.bmcl.2016.02.041>.
- Su, Y., Koike, K., Guo, D., Satou, T., Liu, J., Zheng, J., Nikaido, T., 2001. New apiose-containing triterpenoid saponins from *Conyza blinii*. *Tetrahedron* 57, 6721–6726. [https://doi.org/10.1016/S0040-4020\(01\)00632-9](https://doi.org/10.1016/S0040-4020(01)00632-9).
- Subedi, L., Gaire, B.P., Kim, S., Parveen, A., 2021. Nitric oxide as a target for phytochemicals in anti-neuroinflammatory prevention therapy. *Int. J. Mol. Sci.* 22, 4771. <https://doi.org/10.3390/ijms22094771>.
- Tanaka, T., Nakashima, T., Ueda, T., Tomii, K., Kouno, I., 2007. Facile discrimination of aldose enantiomers by reversed-phase HPLC. *Chem. Pharm. Bull.* 55, 899–901. <https://doi.org/10.1248/cpb.55.899>.
- Vestena, A., Comerlato, L., Bridi, H., Guerini, L., Vidal Ccana-Ccapatinta, G., Vignoli-Silva, M., Apel, M.A., Fernandes, S., Castro-Gamboa, I., Silveira Zuanazzi, J.A., von Poser, G.L., 2019. Chrysoeriol derivatives and other constituents from *Glandularia selloii*. *Phytochem. Lett.* 29, 30–34. <https://doi.org/10.1016/j.phytol.2018.11.003>.
- Vidigal, M.C.S., Cavalheiro, A.J., Kato, M.J., Yoshida, M., 1995. Lignans from kernels of *Virola michelii* heckel. *Phytochemistry* 40, 1259–1261. [https://doi.org/10.1016/0031-9422\(95\)00464-1](https://doi.org/10.1016/0031-9422(95)00464-1).
- Wang, Y.H., Avula, B., Fu, X., Wang, M., Khan, I.A., 2012. Simultaneous determination of the absolute configuration of twelve monosaccharide enantiomers from natural products in a single injection by a UPLC-UV/MS method. *Planta Med.* 78, 834–837. <https://doi.org/10.1055/s-0031-1298432>.
- Yuan, Y.W., Olmstead, R.G., 2008. A species-level phylogenetic study of the Verbenaceae complex (Verbenaceae) indicates two independent intergeneric chloroplast transfers. *Mol. Phylogenet. Evol.* 48, 23–33. <https://doi.org/10.1016/j.ympev.2008.04.004>.
- Zhang, N., Huang, W., Xia, G., Oppong, M.B., Ding, L., Li, P., Qiu, F., 2018. Methods for determination of absolute configuration of monosaccharides. *Chinese Herb. Med.* 10, 14–22. <https://doi.org/10.1016/j.chmed.2017.12.009>.
- Zhao, J., Khan, S.I., Wang, M., Vasquez, Y., Yang, M.H., Avula, B., Wang, Y.H., Avonto, C., Smillie, T.J., Khan, I.A., 2014. Octulosonic acid derivatives from Roman chamomile (*Chamaemelum nobile*) with activities against inflammation and metabolic disorder. *J. Nat. Prod.* 77, 509–515. <https://doi.org/10.1021/np400780n>.
- Zulfiqar, F., Khan, S.I., Ross, S.A., Ali, Z., Khan, I.A., 2017. Prenylated flavonol glycosides from *Epimedii grandiflorum*: cytotoxicity and evaluation against inflammation and metabolic disorder. *Phytochem. Lett.* 20, 160–167. <https://doi.org/10.1016/j.phytol.2017.04.027>.